Spyre Therapeutics, Inc. Common Stock SYRE
$78.63
-2.26%
at last close
Market Cap$7.52 billion
P/E Ratio—
Div Yield—
Volume1.59M
52-Week Range
$14.51$110.17
Analyst Ratings
- Consensus
- Buy — 15 Buy · 1 Hold · 0 Sell (16 analysts)
- Avg. Price Target
- $108.40 (+37.9% upside)
Key Stats
- Today's Range
- $77.95 – $82.45
- 50-Day Range
- $77.05 – $110.17
- 52-Week Range
- $14.51 – $110.17
- Volume
- 1.59 million shs
- Average Volume
- 1.44 million shs
- Market Cap
- $7.52 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.20%
- Days to Cover
- 2.22
About Spyre Therapeutics, Inc. Common Stock
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Related Stocks
Compare head-to-head: SYRE vs LLY·SYRE vs JNJ·SYRE vs ABBV·SYRE vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.